Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Novartis Consumer Health
Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
Telephone: +44 (0)1276 687300
Fax: +44 (0)1276 687284
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1276 687290
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 08/08/2008
SPC Ex-Lax Senna


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Ex-Lax® Senna


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 15 mg of sennosides

For Excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Chocolate bar of tablet


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Relief of occasional constipation


Go to top of the page
4.2 Posology and method of administration

The following doses are normally taken at bedtime

Adults: 1 tablet

Children 6 and over: ½ tablet

Not recommended for children under 6.

There is no indication that the dosage should be modified for the elderly.

Route: Oral route of administration


Go to top of the page
4.3 Contraindications

Ex-Lax Senna should not be used when intestinal obstruction, bleeding or persistent abdominal symptoms are present.

Not recommended in cases of ileostomy or colostomy.


Go to top of the page
4.4 Special warnings and precautions for use

Prolonged use is not recommended. Ex-Lax Senna should not be used for more than 7 days without seeking medical advice.

Label/leaflet precaution:

 

If a laxative is needed every day or there is persistent abdominal pain - consult your doctor.

If there is no bowel movement after 3 days consult your doctor.

Ex-Lax Senna should be used with caution shortly after bowel surgery.

During use of Ex-Lax Senna, an adequate level of fluid intake should be maintained


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

No known adverse effects during pregnancy.

Clinical studies have shown that the breast fed infants mothers taking a senna laxative did not show any side effects to the drug


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

Temporary mild griping may occur.


Go to top of the page
4.9 Overdose

Overdosage may result in diarrhoea with excessive loss of water and electrolytes, particularly potassium. Treatment should include an increase in fluid intake to reverse the loss of fluid and electrolytes. Prolong, excessive use of laxatives without interruption should be avoided because of the risk of electrolyte imbalance and in extreme cases the possibility of irreversible adverse effects on the bowel.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Senna is an anthraquinone laxative which is used to treat constipation and for bowel evacuation before radiological procedures. The active anthraquinones are liberated into the colon from the glycosides by colonic bacteria and an effect usually occurs 6 to 12 hours after administration.


Go to top of the page
5.2 Pharmacokinetic properties

There is some absorption of the anthraquinones from senna preparations following hydrolysis by colonic bacteria. Excretion occurs in the urine and the faeces and also in other secretions including milk.

(Although anthraquinone derivatives may be excreted in the milk of lactating mothers, following normal dosage the concentration is usually insufficient to affect the nursing infant)


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Confectionery chocolate comprising:

Cocoa liquor

Sucrose

Cocoa butter

Lecithin

Vanilin


Go to top of the page
6.2 Incompatibilities

None known


Go to top of the page
6.3 Shelf life

60 months


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C


Go to top of the page
6.5 Nature and contents of container

Bars of 6, 9 and 12 tablets wrapped in paper backed aluminium foil, or aluminium foil, and packed into cartons.

Pack sizes: 6, 9, 12, 18, 24, 36 or 48 tablets.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Novartis Consumer Health UK Ltd.

Wimblehurst Road

Horsham

West Sussex

RH12 5AB

United Kingdom

Trading as Novartis Consumer Health


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 00030/0131


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

01 July 1997


Go to top of the page
10. DATE OF REVISION OF THE TEXT

15 December 2006

Legal category: GSL



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/21078/SPC/


Active Ingredients/Generics

 
  sennoside